Forte Biosciences, Inc. (FBRX) - 10-K Summary
Business Context and Reporting Period
Company: Forte Biosciences, Inc.
Filing Type: Annual Report on Form 10-K
Period: Fiscal year ended December 31, 2024
Business Overview: Forte is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody. FB102 targets autoimmune and autoimmune-related indications, including celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(35,478) | $(31,476) |
| Research & Development Expenses | $21,193 | $21,862 |
| General & Administrative Expenses | $15,409 | $10,624 |
| Cash, Cash Equivalents & Short-Term Investments | $58,365 | $37,125 |
| Accumulated Deficit | $(153,998) | $(118,520) |
| Net Cash Used in Operating Activities | $(30,745) | $(28,706) |
| Net Cash Provided by Financing Activities | $51,857 | $24,684 |
Note: The company reported a net loss per share of $(12.17) for 2024 compared to $(24.92) for 2023.
Material Changes vs. Prior Period
- Financing Activity: In November 2024, the company completed a private placement raising gross proceeds of $53.0 million (net of $3.4 million issuance costs) through the issuance of common stock and pre-funded warrants. This significantly increased cash reserves compared to the $25.0 million raised in a similar 2023 private placement.
- Operating Expenses: Total operating expenses increased by $4.1 million to $36.6 million. This was driven primarily by a $4.8 million increase in General and Administrative expenses due to higher professional and legal fees, partially offset by a $0.7 million decrease in R&D expenses.
- R&D Composition: The decrease in R&D expenses was due to a $7.0 million reduction in manufacturing costs, offset by a $5.5 million increase in preclinical and clinical expenses as the FB102 program entered patient trials.
- Stock Structure: The company effected a 1-for-25 reverse stock split in August 2024 to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, and Risks
Outlook and Milestones:
- FB102 Development: Phase 1 healthy volunteer trials are complete with a good safety profile. A patient-based trial for celiac disease initiated in Q3 2024 is currently enrolling, with top-line results expected in Q2 2025.
- Liquidity: Management believes current cash resources ($58.4 million) are sufficient to fund operations for at least 12 months from the filing date. However, the company expects to incur significant losses in the foreseeable future and will require additional capital to complete clinical development.
- Capital Constraints: The company's Form S-3 shelf registration expired in June 2024. While an "At-The-Market" (ATM) facility exists, the company is currently restricted in its ability to sell securities under Form S-3 due to its public float being below $75.0 million.
Risks and Contingencies:
- Capital Requirements: Failure to secure additional financing could force the company to delay, scale back, or discontinue development of FB102.
- Clinical Uncertainty: FB102 is the company's sole product candidate. Early positive results do not guarantee success in later-stage trials or regulatory approval.
- Legal Proceedings: The company resolved a shareholder lawsuit (Camac Fund) in September 2024 by paying $1.5 million in legal fees and entering into standstill agreements. The company also filed a lawsuit against its D&O insurance carriers regarding coverage for these legal costs.
- Intellectual Property: The company is involved in a post-grant review regarding a third-party patent (University of Massachusetts) that claims broad autoimmune technologies. While the PTAB found the patent unpatentable, the University has appealed.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the 12-month liquidity projection given the high burn rate and lack of revenue.
- Financing Restrictions: Confirm the status of the Form S-3 registration and the specific limitations on the ATM facility due to the $75 million public float threshold.
- Clinical Trial Progress: Monitor enrollment rates and safety data for the celiac disease trial, with results expected in Q2 2025.
- Legal Exposure: Review the outcome of the appeal regarding the University of Massachusetts patent and the status of the lawsuit against D&O insurers.
- Stock Dilution: Assess the impact of outstanding pre-funded warrants (approx. 5 million shares) and the potential for future dilutive equity raises.